Use of Cast Iron Pots to Improve Maternal Anemia
NCT02341300 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34
Last updated 2020-07-30
Summary
Anemia of pregnancy is defined as a hemoglobin concentration of less than 11 g/dL in the first and third trimesters, and less than 10.5 g/dL in the second trimester. The rates of anemia are variable and depend largely on preexisting iron stores and supplementation. Estimates from the World Health Organization report that 35% to 75% of pregnant women in developing countries and 18% of women from industrialized countries are anemic. Maternal anemia is associated with an increased risk of preterm birth, low birthweight, and small for gestational age infants. Many studies have shown improvement in these outcomes with maternal iron supplementation in cases of iron-deficiency anemia. Mounting evidence also indicates that maternal iron deficiency in pregnancy reduces fetal iron stores, perhaps well into the first year of life.
Anemia in pregnancy can also impact maternal morbidity and mortality. Viteri reported that anemic pregnant women are at greater risk of death during the perinatal period and that anemia is the major contributory or sole cause of death in 20-40% of the 500,000 maternal deaths per year.
The need for iron averages close to 1000mg in a typical singleton gestation. This amount considerably exceeds the iron stores of most women and will result in iron-deficiency anemia unless supplemental iron is taken. One problem with iron supplement use is compliance, secondary to adverse effects such as constipation and nausea. Research on the use of cast iron pots in decreasing the incidence of iron-deficiency anemia in non-pregnant women has been promising. These studies have demonstrated good compliance with no reported adverse effects. The aim of our study is to determine if providing anemic women in the first trimester of pregnancy with a cast iron pot will decrease the incidence of anemia later in pregnancy.
Hypothesis: Cooking in cast iron pots will increase hematocrit levels in pregnancy.
Conditions
- Iron-deficiency Anemia
Interventions
- DEVICE
-
Cast Iron Pot
Cast iron pot
- DEVICE
-
Alumnium Pot
Aluminum Skillet
Sponsors & Collaborators
-
Weill Medical College of Cornell University
lead OTHER
Principal Investigators
-
Stephen Chasen, MD · New York Presbyterian Hospital Weill Cornell
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-07-15
- Primary Completion
- 2020-07-15
- Completion
- 2020-07-15
Countries
- United States
Study Locations
More Related Trials
-
Cord Blood S100B Protein Levels in Neonates Following Intrauterine Transfusions for HDFN-Associated Fetal Anemia
NCT06984445 ·Status: RECRUITING
-
Effect of Erythropoietin on Preterm Brain Injury
NCT02036073 ·Status: COMPLETED ·Phase: PHASE4
-
Association of Red Blood Cell Transfusion, Anemia, and Necrotizing Enterocolitis
NCT04921696 ·Status: WITHDRAWN
-
Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants
NCT05340465 ·Status: RECRUITING ·Phase: PHASE2
-
Effect of Erythropoietin on Neurodevelopmental Outcomes in Very Preterm Infants With Intraventricular Hemorrhage
NCT03914690 ·Status: COMPLETED ·Phase: PHASE2
-
Whole-Body Hypothermia for Neonates With Hypoxic-Ischemic Encephalopathy(HIE)
NCT05581927 ·Status: WITHDRAWN ·Phase: NA
-
Serum Erythropoietin Level in Perinatal Asphyxia
NCT05018364 ·Status: COMPLETED
-
Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic CHD - A Prospective Control Trial
NCT02564796 ·Status: TERMINATED ·Phase: PHASE2
-
Near-Infrared Spectroscopy and Cranial Doppler in Premature Newborns With Anemia
NCT04509375 ·Status: UNKNOWN
-
Erythropoietin Treatment in Extremely Low Birth Weight Infants
NCT00593801 ·Status: COMPLETED ·Phase: NA
-
Analyses of Anemia in Very Low Birth Weight (VLBW) Infants.
NCT05949788 ·Status: COMPLETED
-
Effect of Erythropoietin in Premature Infants on White Matter Lesions and Neurodevelopmental Outcome
NCT03110341 ·Status: UNKNOWN ·Phase: PHASE3
-
Red Blood Cell (RBC) Survival Following Transfusion in Infants
NCT00731588 ·Status: COMPLETED ·Phase: PHASE2
-
Intravenous Immunoglobin Transfusion in Preterm Infants With Encephalopathy of Prematurity
NCT02822027 ·Status: UNKNOWN ·Phase: NA
-
Erythropoietin Protects Very Preterm Infants Against Necrotizing Enterocolitis
NCT03919500 ·Status: COMPLETED ·Phase: PHASE2
-
Premature Infants in Need of Transfusion (PINT)
NCT00182390 ·Status: COMPLETED ·Phase: PHASE3
-
Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy
NCT02551003 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Identification of Jaundice in Newborns Using Smartphones
NCT04182555 ·Status: COMPLETED ·Phase: NA
-
Darbepoetin Administration to Preterm Infants
NCT00334737 ·Status: COMPLETED ·Phase: PHASE2
-
Iron Supplementation of Marginally Low Birth Weight Infants
NCT00558454 ·Status: COMPLETED ·Phase: PHASE4
-
Heparin Responses in Pediatric Patients Undergoing Cardiopulmonary Bypass.
NCT00166140 ·Status: COMPLETED
-
Comparison of the Rate of Preoperative Haemoglobin After Administration of Epoetin Alpha Associated With an Oral Medical Supplementation Versus Intravenous Before Surgery of Craniosynostosis at the Child
NCT03231085 ·Status: COMPLETED ·Phase: NA
-
In-utero Hematopoietic Stem Cell Transplantation for the Treatment of Fetuses With Bart's Hydrops Fetalis Syndrome
NCT05797272 ·Status: RECRUITING ·Phase: NA
-
High-dose Erythropoietin for Asphyxia and Encephalopathy
NCT02811263 ·Status: COMPLETED ·Phase: PHASE3
-
Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants
NCT00910234 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2